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Abstract: Osteopontin (OPN) is recognized for its significant roles in both physiological and
pathological processes. Initially, OPN was recognized as a cytokine with pro-inflammatory actions.
More recently, OPN has emerged as a matricellular protein of the extracellular matrix (ECM). OPN is
also known to be a substrate for proteolytic cleavage by several proteases that form an integral part
of the ECM. In the adult heart under physiological conditions, basal levels of OPN are expressed.
Increased expression of OPN has been correlated with the progression of cardiac remodeling and
fibrosis to heart failure and the severity of the condition. The intricate process by which OPN
mediates its effects include the coordination of intracellular signals necessary for the differentiation of
fibroblasts into myofibroblasts, promoting angiogenesis, wound healing, and tissue regeneration.
In this review, we discuss the role of OPN in contributing to the development of cardiac fibrosis and
its suitability as a therapeutic target.
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1. Introduction
Cardiovascular diseases are the number one cause of death globally with more people dying
annually from cardiovascular diseases than from any other cause. [1,2]. Unlike most tissues, the heart
is unable to repair itself because of the lack of sufficient cardiomyocyte proliferation. Wound healing
plays a critical role in maintaining adequate heart function following cardiomyocyte death. This
includes chronic extracellular matrix (ECM) deposition by myofibroblasts and further expansion of
the scar [3]. Cardiac fibrosis is characterized by net accumulation of extracellular matrix proteins in
the cardiac interstitium and contributes to both systolic and diastolic dysfunction in many cardiac
pathophysiologic conditions [3]. It is a common theme in several types of heart diseases, including
inherited cardiomyopathies, ischemic heart disease, diabetes and obesity, and ageing, and has been
linked to morbidity and mortality [3]. During cardiac fibrosis, cardiac fibroblasts transform to
a myofibroblast phenotype [3,4]. These myofibroblasts are responsible for the production of the
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extracellular matrix (ECM) and activation of several inflammatory pathways [5]. The early stages of
this “healing” process promote the formation of a scar. The scar tissue is gradually substituted with
new cells [6]. Failure to terminate the wound-healing program provokes a cascade of pathological
changes that consequently result in cardiomyocyte hypertrophy, apoptosis, chamber dilatation,
and ultimately, the development of congestive heart failure [3]. As a result, the interconversion of
fibroblasts to myofibroblasts is prolonged. Alterations of the myocardial architecture of the injured heart
contributes to impaired cardiac function and ventricular stiffness, leading to contractile dysfunction [4].
The accumulation of the ECM can also alter the mechano-electric coupling of cardiomyocytes, thereby
amplifying the risk of arrhythmogenicity. This in turn exacerbates the progression towards heart failure
and even sudden cardiac death [5]. Moreover, in dilated cardiomyopathy (DCM), elevated collagen
synthesis and degradation have also been reported in the pathology of ECM fibrosis [7]. ECM fibrosis
has been characterized by an overexpression of matrix metalloproteinases (MMPs) [7–9]. Although
activated myofibroblasts are the main effector cells in the fibrotic heart, monocytes/macrophages,
lymphocytes, mast cells, vascular cells, and cardiomyocytes may also contribute to the fibrotic response
by secreting key fibrogenic mediators [5,8,9].
Regardless of the pathophysiologic injury leading to fibrotic remodeling of the ventricle,
the networks of molecular signals involved are similar in various cardiac diseases [5,8]. Indeed,
the relative contribution of each pathway is often dependent on the underlying cause of fibrotic
remodeling [5]. Inflammatory cytokines and chemokines, reactive oxygen species, mast cell-derived
proteases, endothelin-1, the renin/angiotensin/aldosterone system, matricellular proteins, and growth
factors (such as transforming growth factor beta (TGF-β)) are implicated in cardiac fibrosis [8,9].
Inflammatory signals seem to be more important in reparative and ischemic fibrosis, while
angiotensin/aldosterone axis and fibrogenic growth factors, such as TGF-β, appear to be involved
in most fibrotic cardiac conditions regardless of the etiology [5]. Understanding the mechanisms
responsible for the initiation and subsequent progression of cardiac fibrosis are crucial to identify
effective anti-fibrotic treatment options. It has been demonstrated that cardiac injury promotes the
activation of the renin–angiotensin–aldosterone system (RAAS), of which angiotensin II (Ang-II)
appears to be the principal effector [4]. Ang II is heavily involved with the inflammatory response
since it is activated and expressed by both macrophages as well as myofibroblasts [3]. In turn, this is
thought to induce transforming growth factor β (TGF-β) signaling, which promotes the expression
of genes that are characteristic of myofibroblast transdifferentiation, including α-smooth muscle
actin, the extra domain-A fibronectin (ED-A FN), endothelin 1, connective tissue growth factor,
and osteopontin (OPN), all which also serve as promoters of wound healing and fibrotic changes
following cardiac injury [5,10]. ACE inhibition and AT1 blockade in patients with chronic heart failure
or acute myocardial infarction has demonstrated to be beneficial, which in part maybe due to the
inhibition of the angiotensin-induced fibrogenic actions. Aldosterone has also been demonstrated to
induce fibrotic changes in the myocardium [5].In addition, the expression of the pro-inflammatory
cytokines, such as TNF-α, interleukin 1 beta (IL-1β), and IL-6, are consistently induced in fibrotic
hearts [5].Clearly, understanding the mechanisms that contribute to cardiac fibrosis provides further
direction in identifying novel therapeutic interventions.
OPN plays an important role in a variety of cellular activities associated with inflammatory
and fibrotic cascades, as well as wound healing [11,12]. It could act both as a matricellular protein
(when bound to the matrix) and as a cytokine, when secreted in a soluble form [5]. In the unstressed
heart, rat ventricular cardiomyocytes have been shown to express basal levels of OPN [13,14].
Interestingly, OPN expression has been demonstrated to be elevated upon the onset of cardiac
hypertrophy (CH), suggesting its role as an effector for extracellular signaling, which induces myocyte
growth [15]. In fibrotic lesions and healing wounds, both of which are characterized by myofibroblast
differentiation, the expression of OPN is also markedly high [16]. Increased OPN levels have also
been demonstrated both in the myocardium and plasma of patients with both DCM and hypertrophic
cardiomyopathy (HCM), seemingly as a result of fibroblast activation [16]. OPN expression is also
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marked in heart failure of both ischemic and non-ischemic origin, as well as myocardial infarction
(MI) [5,17]. In several experimental animal models, including MI, ischemia perfusion injury, and Ang-II
or aldosterone-infusion, the downregulation of OPN was associated with a marked reduction in
myocyte apoptosis and improved cardiac function [14,17]. Although elevated OPN activity has been
detected in both myocytes and fibroblasts experiencing stress, there appears to be no indication of
the long-term and lasting effects of blocking OPN signaling on the heart [15]. Therefore, a better
understanding of the role of OPN in the pathogenesis of cardiac fibrosis, a common theme in various
types of cardiovascular diseases, could hold the key to the identification of promising therapeutic
targets for the treatment of patients with heart failure.
2. Osteopontin Structure
OPN was initially described in 1979 as a “secreted phosphoprotein” associated with malignant
transformations in cancerous cell lines [18]. In 1985, it was first described as “sialoprotein” after
its isolation from osteoblasts and osteoclasts [19]. A year later, in 1986, its cell binding sequence
was identified and it was renamed OPN, meaning “bone-bridge” [19]. The expression of OPN
was also detected in other cell types, including fibroblasts and macrophages [14], demonstrating its
inflammatory role and interaction with the immune system [20]. OPN is an acidic-hydrophilic member
of the matricellular protein family, a class of non-structural ECM proteins [17]. Alternative splicing of
OPN results in three isoforms, OPN-a (the full-length isoform), OPN-b (which lacks exon 5), and OPN-c
(which lacks exon 4) [21]. The full-length human OPN protein is made up of 314 amino acid residues
with a predicted molecular mass of around 32 kDa [22], while the OPN-b and OPN-c isoforms are
made up of 300 and 287 amino acids, respectively [23]. The functional significance of deleting this
amino acid segment is unknown. The OPN coding sequence seems to be highly conserved amongst
species [14]. The apparent molecular weight of OPN can range from 45–75 kDa on gel electrophoresis
due to extensive post-translational modification (PTM) caused by phosphorylation, glycosylation, and
sulfation [14,19,24]. This has also been attributed to the high density of negative charges throughout the
protein from the predominance of acidic amino acids, as well as the multitude of serine phosphorylation
sites [22]. The significance of PTM is to facilitate the activation of OPN [19,20]. It has also been
suggested that PTM leads to tissue-specific isoforms of OPN [25]. The diverse biological functions
of OPN can be attributable due to its structural features, PTMs, interaction with multiple receptors,
and different isoforms [5,17]. Alternative translation of OPN generates two isoforms: A cell-secreted
full length OPN (sOPN) and a shortened protein lacking the N-terminal signal sequence of sOPN,
intracellular (iOPN), found in the cytoplasm and nucleus [26]. Studies investigating the involvement of
OPN in cardiovascular diseases primarily focus on total OPN expression and do not take into account
the expression levels of any specific OPN isoform [21].
OPN carries various functional domains, which allow for receptor binding for the
promotion of several biological functions. The N-terminal contains the arginine-glycine-aspartate
(RGD) cell binding sequence (Figure 1) [22]. The N-terminal also carries a non-RGD
serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR) domain between the RGD cell
binding sequence and the thrombin cleavage site. This domain allows for the interaction between OPN
and integrin receptors α4β1 and α9β1, respectively [22]. OPN also contains two recognized heparin
bindings sites as well as a calcium (Ca2+) binding site near the C-terminal of the protein (Figure 1) [24].
Additionally, transglutamination allows OPN to be cross-linked to itself or other proteins by using
two of its highly conserved glutamine residues. The process of transglutamination increases OPN’s
collagen-binding abilities [20].
Nuclear magnetic resonance studies have indicated that OPN is a biologically active protein that
typically lacks a defined tertiary, and often secondary, structure [27]. Recent computer algorithms were
able to predict the existence of some secondary structures composed of short α-helices and β-strand
structures [25]. These abnormal conformities suggest the possible interactions of the C-terminal domain
of OPN with the central RGD-SVVYGLR integrin-binding domain [25].
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Figure 1. Structural features of the osteopontin (OPN) full-length secreted
isoform with six translated exons (314 amino acids). OPN isoforms include the
following functional domains: Arginine-glycine-aspartic acid (RGD) domain (159–161),
serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR) domain (162–168), thrombin
cleavage site, calcium binding domain (216–228), and heparin binding domain. Integrin binding occurs
at RGD and SVVYGLR sequences. CD44 variant receptor binding occurs near the C-terminus and
N-terminus. Phosphorylation sites exist across the precursor-mRNA (pre-mRNA). All OPN isoforms
have thrombin and matrix metalloproteinase (MMP) cleavage sites.
3. Physiological Function of OPN
OPN has emerged as a key ubiquitous phosphoprotein involved in numerous biological functions,
including biomineralization, ECM and tissue remodeling and repair, immunity and the inflammatory
response, cell death, and survival (Figure 2) [24,26,28]. OPN’s conformational flexibility mediates its
interaction with a multitude of ligands across a dynamic array of cellular surfaces [27]. The interaction
of the N-domain with αvβ1, αvβ3, and αvβ5 integrin receptors has been shown to mediate
cell migration [20,28]. In rat aortic smooth muscle cells, OPN mediates platelet-derived growth
factor migration from the media to the intima of arteries [29]. It is strongly expressed during
injury-induced vessel calcification and is vital for inhibiting this vascular calcification in smooth
muscle cells in mice [25]. Interestingly, PTM of OPN can impact its biological functions [17], where the
un-phosphorylated or enzymatically dephosphorylated OPN appears to have no effect in mice [14] and
the native phosphorylated form of OPN is able to inhibit calcification of human smooth muscle cells
in vitro [17]. Moreover, OPN promotes macrophage and endothelial cell migration and proliferation,
thus contributing to vasculature remodeling [30].
Figure 2. As a multifunctional protein, OPN plays a crucial role in several biological processes,
including inflammation and the immune response (as a chemical attractant for macrophages and T cells,
and a modulator of T-cell responses), biomineralization (by modulating the adherence of osseous cells,
and modulation of both osteoclastic function and matrix mineralization), and tissue remodeling and
repair (by modulating apoptosis, and secretion of metalloproteinase (MMPs) as well the regeneration
and differentiation of fibroblasts and myofibroblasts).
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OPN is also an important regulator of apoptosis [28]. OPN’s pro-survival properties have also
been attributed to the binding of phosphoprotein with the αvβ3 integrin receptor, in addition to
activation of downstream nuclear factor-kappa β (NFkB) signaling [31]. OPN is also thought to
interact with hyaluronic acid receptor 44 (CD44) via the Ca2+ binding site [24], along with N-terminal,
thereby allowing OPN to regulate CD44 surface expression [19,22]. The anti-apoptotic actions of OPN
have also been attributed to its interaction with the CD44 receptor and activation of the downstream
phosphoinositide 3 (PI-3)-kinase/protein kinase B (Akt) cascade [17].
OPN appears to play an important role in wound healing due to its effects on cell viability, as well
as modulating the secretion of MMPs, and the proliferation and differentiation of fibroblasts [28].
At the wound site, OPN also serves as a chemotactic molecule to promote macrophage infiltration
and recruit inflammatory cells, as well as acting as an adhesive protein to retain cells at the site of
injury [30]. OPN’s role in promoting wound healing has also been attributed to its ability to bind
directly to collagen type I and interact with collagen types II, III, IV, and V, as evident by the alterations
in collagen fiber diameter observed in OPN-null mice enduring incisional wounds [30]. OPN is an
important angiogenic factor, could act as a chemo-attractant, and is shown to promote vascular cell
adhesion and spreading in vitro [22]. OPN’s ability to promote angiogenesis has been attributed
to its action directly through PI3K/AKT- and extracellular signal-regulated kinase (ERK)-mediated
pathways, which enhances the expression of vascular endothelial growth factor (VEGF), and vascular
permeability factor (VPF), cytokines that have been shown to induce angiogenesis [21].
In bones, OPN is one of the more abundant non-collagenous proteins whose phosphorylation
provides a stabilizing effect on the bond between calcium and hydroxyapatite, thus serving as an
attachment protein linking cells to the bone mineral [25]. It also facilitates the attachment of osteoclasts
to the bone matrix via an interaction with CD44 and cell surface αvβ3 integrin receptor. OPN has also
been shown to act through the Ca2+ -NFAT (nuclear factor of activated T cells) pathway to promote
osteoclast survival and increase bone resorption [22]. iOPN also plays a role in osteoclast motility,
fusion, and resorption, and could be responsible for some of the observed effects of OPN deficiency,
including bone loss due to reduced mechanical stress [25]. In the immune system, OPN facilitates
chemotaxis, leading to the migration of macrophages and dendritic cells to sites of inflammation [28].
It has also been shown that OPN can modulate the immune response by macrophage recruitment
and differentiation, enhanced expression of Th1 cytokines and matrix-degrading enzymes, as well
as phagocytosis in mice [30]. OPN’s role in the inflammatory process has also been attributed to
the binding of phosphoprotein with the integrin receptor, leading to NFkB-mediated expression of
inflammatory cytokines [22].
As a matricellular protein, OPN appears to function as a modulator of cell–ECM interactions,
often achieved by binding to growth factors, structural matrix proteins, proteases, and cell-surface
receptors, rendering them essential components of the ECM environment [24]. One of the features of
OPN’s structure that has a huge impact on its biological function is the presence of a thrombin-cleavage
site, which allows the protein to be cleaved into two fragments: The N-terminal (amino) fragment
carrying both RGD and SVVYGLR domains, and a C-terminal (carboxyl) fragment, which contains the
Ca2+ and 2 heparin binding sites [19]. It appears that the N-terminal fragment possesses adhesion
motifs that may render it even more biologically active than the full-length OPN protein whereas the
properties of the C-terminal fragment of OPN are less well characterized [32]. OPN is also susceptible
to cleavage by different proteolytic MMPs (MMP 2,3,7,9), which form an integral part of the ECM [32].
Each MMP yields a unique cleavage profile, with only few overlapping cleavage sites giving peptides
that can exert distinct biological functions. Data from carotid-plaque samples of hypertensive patients
have also recently suggested that the cleavage of OPN further enhances the ability of the RGD binding
site to interact with the CD44 as well as αvβ1, αvβ3, and αvβ5 integrin receptors, thus magnifying the
cell adherence capabilities of OPN [32], and rendering OPN an integral component for the homeostasis
of the ECM environment.
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4. Role of OPN in Heart Disease
For the heart to continue to function in a state of equilibrium, very intricate crosstalk between the
different types of cells residing in the heart, as well as their interaction with the ECM, is orchestrated [33].
While cardiomyocytes constitute approximately two thirds of the myocardial tissue volume, cardiac
fibroblasts actually have the highest cell population in the myocardium (accounting for approximately
two thirds of the overall cells) [9]. OPN expression in the adult heart is detected at basal levels,
as observed by northern blot analysis of fresh primary isolates of adult rat ventricular myocytes [14].
Fibroblasts and microvascular endothelial cells have also been shown to express low basal levels of
OPN under physiological conditions [17]. The lack of OPN in experimental models of MI injury in
rats showed signs of reduced repair as evident by reduced collagen synthesis and deposition in both
infarct and non-infarct regions, resulting in ventricular dilation [34]. On the other hand, there appears
to be a strong correlation between OPN levels and the severity of several cardiac pathologies [19].
Rubis et al. recently demonstrated that elevated levels of OPN were found to be related to more
severe cardiovascular outcomes in an observational, prospective cohort study of DCM [7]. Moreover,
human myocytes isolated from explanted hearts with either idiopathic or ischemic cardiomyopathy
presenting with extensive fibrosis and CH demonstrated substantial immunoreactivity for OPN [14].
In fact, elevated expression of OPN has also been shown to be associated with the development of
heart failure [35]. Thus, OPN emerges as a double-edged sword during cardiac adaptation and disease,
where initially, it is heavily involved with cardiac repair following ischemic injury; on the other hand,
OPN expression appears to be markedly increased in the heart under different pathological states.
Enhanced expression of OPN appears to play an important role in the remodeling of the heart
post-MI, as well as in left ventricular hypertrophy [36–39]. One putative route through which the OPN
could be mediating its hypertrophic effects is through the activation of pro-hypertrophic kinases and
pathways. Interestingly, levels of phosphorylated Akt and glycogen synthase kinase-3β (GSK-3β)
were significantly higher in mice subjected to aortic banding that develop CH [37]. Phosphorylation of
GSK-3β enhances the translocation of NFAT and GATA-4 transcription factors to the nucleus, inducing
hypertrophic gene expression [13,22]. The calcineurin (CaN)/nuclear factor of activated T-cells (NFAT)
pathway has also been highlighted as a possible pathway for OPN to mediate CH [13,40]. This
was emphasized in a study in which the activation of NFATc1 and GATA-3 (both pro-hypertrophic
factors) were significantly reduced in OPN-deficient mice [41]. OPN has also recently been shown
to mediate the hypertrophic response induced by cardiomyocyte expression of the activated form of
Na+/H+ exchanger isoform 1 (NHE1) [13,39,40,42]. Transgenic mice expressing active, cardiac-specific
NHE1 showed alterations in gene expression that led to both CH and an upregulation of OPN as
well as its related molecules, including fibronectin, CD44, integrin receptors, MMPs, and signaling
kinases [42]. Interestingly, transfection of cardiomyocytes with siRNA-OPN significantly abolished
the NHE1-induced hypertrophic response, as well as significantly reducing the activity of NHE1 in
cardiomyocytes expressing active NHE1 [13]. Moreover, in the double transgenic mice expressing
active NHE1 in which OPN was knocked out, cardiac hypertrophic parameters, including increased
collagen deposition, upregulation of CD44, and phosphorylation of p90 ribosomal s6 kinase (RSK),
were significantly reduced when compared to NHE1 transgenic mice [39]. In another model where CH
was induced by transverse aortic constriction (TAC) in serum- and glucocorticoid-inducible kinase
(SGK1) SGK1+/+ mice, a marked increase in both OPN and NHE1 expression/activity was shown [43].
These findings further implicate OPN in mediating the hypertrophic effects observed in different
models of CH.
OPN also appears to play a role in several cardiomyopathies, including diabetic cardiomyopathy,
in vivo [44,45] DCM both in mice [46] and in humans [7] and in patients with HCM [26]. The implication
of OPN in idiopathic cardiomyopathies was also observed in hearts explanted at the time of
cardiac transplantation, revealing an upregulation of OPN in cardiomyocytes [47]. Although the
exact mechanism through which OPN mediates diabetic cardiomyopathy is not fully understood,
Nilsson-Berglund et al. recently identified two NFATc3 responsive sequences in the OPN promoter
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driving its expression in diabetic mice [45]. Conversely, OPN expression was significantly reduced
in arteries from the diabetic NFAT knockout (KO) mice [45]. In another study, Subramanian et al.
suggested that activation of protein kinase C (PKC)-βII could be mediating the upregulation of OPN in
a mouse model of diabetic cardiomyopathy [44]. Interestingly, Soetikno et al. revealed that curcumin
attenuated diabetes-induced cardiomyopathy in mice through the reduction of OPN expression and
PKC-βII activity [48]. Collectively, these findings have important clinical implications, as they indicate
that the inhibition of selected pathways or ligands involved in the OPN pathway may be of therapeutic
benefit for the prevention of further cardiac damage and dysfunction.
OPN may also play an important part in the inflammatory process of atherosclerosis [22].
It has been suggested that OPN plays a role in the migration of endothelial cells, proliferation,
and/or differentiation of vascular smooth muscle cells (VSMCs) along with plaque progression and
dystrophic calcification [19]. OPN also has the ability to promote macrophage and VSMC accumulation,
thus contributing to vasculature remodeling both in vivo and in humans [30]. An early study has
demonstrated that VPF/VEGF activation in human dermal microvascular endothelial cells increases
the expression of αvβ3 and its ligand OPN on the cell surface, which contributes to the migration of
endothelial cells and macrophages [19]. OPN’s migration-promoting activity is further enhanced by
thrombin cleavage of OPN as observed in carotid plaques from hypertensive patients [32]. Moreover,
Lee et al. demonstrated that the human OPN isoforms OPN-a, OPN-b, or OPN-c, which are not
expressed in rodents, may represent a novel therapeutic target to improve neovascualrization and
preserve tissue function in patients with obstructive artery diseases [24]. [OPNa and OPNc significantly
improved limb perfusion in OPN−/− mice who underwent hindlimb ischemia surgery while OPN-a
and OPN-c treated animals exhibited significant increases in arteriogenesis [24]. These findings suggest
that the apparent role of OPN in both cardiac and vascular injuries make it an ideal therapeutic target
to prevent irreversible damage to the myocardium.
5. Role of OPN in Cardiac Fibrosis
Injury to the heart can result in the amplification of resident cardiac fibroblasts, the transformation
of endothelial/epithelial cells to fibroblasts, and even the recruitment of hematopoietic cells to the site of
injury and their transformation into cardiac fibroblasts and myofibroblasts [49]. This cascade of complex
cellular and molecular interactions determines successful recovery or inadequate repair of the damaged
tissue in the heart. OPN is essential for the differentiation of fibroblasts into myofibroblasts post-MI
injury, as documented and demonstrated by several studies [6,14,16,22,46,47,50–55]. These activated
fibroblasts and myofibroblasts become the source of ECM proteins necessary for scar formation
and healing of infarcted regions of the heart [6]. However, failure to terminate this wound-healing
process results in persistent activation of fibroblasts and excessive cardiac remodeling associated with
cardiomyocyte death, myocardial degeneration, impaired ventricular relaxation, and overall cardiac
decompensation [8,10,15,49]. This cascade of events has been suggested to further increase the release
of OPN from cardiomyocytes, thereby increasing OPN expression in infarct as well as non-infarct
regions of the heart post-MI [56].
Activation of the renin-angiotensin-aldosterone system (RAAS), and consequent release of Ang-II
post-MI has been shown to induce the expression of OPN in both neonatal and adult rat cardiac
fibroblasts (NRCFs and ARCFs) [14]. Ang-II-induced activation of OPN has been suggested to occur in
part through the ERK1/2 and c-Jun N-terminal kinases (JNK) pathways in ARCFs [57]. The production
of reactive oxygen species appears to be a common mechanism involved in the increased expression
of OPN from ARCFs post-MI [22]. Indeed, Ang-II induced significant phosphorylation of p42/44
mitogen-activated protein kinase (MAPK) and increased superoxide production, effects that were
blocked by an NADPH oxidase inhibitor [14]. In addition, the inhibition of JNKs in ARCFs, combined
with inhibition of ERK1/2, was able to almost completely inhibit Ang-II-mediated upregulation of
OPN [57]. Taken together, these studies highlight some of the potential signaling pathways that
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mediate the Ang-II-induced increase of OPN expression in interstitial cells and the heart post-MI
(Figure 3).
Figure 3. Role of osteopontin in cardiovascular disease and cardiac fibrosis, dilated cardiomyopathy
(DCM), and hypertrophic cardiomyopathy (HCM), seemingly as a result of fibroblast activation.
Elevated collagen synthesis and degradation have also been reported in the pathology of extracellular
matrix (ECM) fibrosis. The calcineurin-NFAT pathway and activation of protein kinase C-βII could
be mediating the upregulation of OPN in diabetic cardiomyopathy. In several models of cardiac
hypertrophy and heart failure, OPN has been shown to induce the activation of several pro-hypertrophic
kinases and pathways, including: p90 ribosomal s6 kinase, Akt, glycogen synthase kinase-3β,
NFAT/GATA-4, calcineurin-NFAT, and serum- and glucocorticoid-inducible kinase. OPN has also
been implicated in atherosclerosis and the process of neointima and plaque formation and dystrophic
calcification by orchestrating the immune response and vascular smooth muscle cell migration. While
upregulation of OPN in the heart following injury has the potential to protect against left ventricular
dilation, it can also increase cardiac fibrosis and induce pathological remodeling through excessive
myofibroblast differentiation, increased extracellular matrix, collagen synthesis, and deposition. This
appears to involve the activation of downstream signaling pathways, including the mitogen-activated
protein kinase (MAPK), extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinases (JNK),
and phosphorylation of RSK; as well as the PI3K/Akt pathway. The interaction between OPN, CD44, and
integrins has also been suggested to further promote tissue fibrosis and decrease the cardioprotective
effects of the β2-adrenergic receptor (β2AR).
Many studies have demonstrated the efficacy of partial or complete OPN inhibition in a variety of
preclinical models of diseases, including CH [15,37,39], coronary artery disease [24,28,58,59], DCM [46],
diabetic cardiomyopathy [48], heart failure [52], and cardiac fibrosis [13,15,38,39,60]. The earliest study
by Matsui et al. demonstrated that the Ang-II-induced elevation in blood pressure, collagen deposition,
and development of cardiac fibrosis was significantly reduced in OPN−/− mice compared to wild type
(WT) mice [38]. However, the reduction of cardiac fibrosis led to an impairment of cardiac systolic
function and subsequent left ventricular dilation in the OPN−/− mice [38], suggesting that completely
knocking out OPN in the heart can actually decrease the intrinsic repair mechanism following Ang-II
infusion, resulting in side-to-side slippage of cardiomyocytes and the impairment observed. This is in
line with previous results, which demonstrated that OPN deficiency in a murine model of MI caused
exaggeration of left ventricular dilation and reduction of collagen deposition in comparison with WT
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mice [59]. These findings raise the question of whether the use of more specific inhibitors or deletion
of specific OPN isoforms in the heart post-MI could be more beneficial for regressing cardiac fibrosis.
Using the streptozotocin-induced diabetic cardiomyopathy mouse model, Subramanian et al.
demonstrated that the increase in fibrosis was significantly lower in OPN-/- versus WT mice, which
was also associated with lower TGF-β levels [48]. These findings suggest that the lack of OPN can
actually be beneficial in reducing myocardial fibrosis in the diabetic heart. In another study where the
genetic model of heart failure was examined (double desmin−/−OPN−/− mice), the deficiency in OPN
reduced fibrosis and improved the systolic properties of desmin−/− myocardium [52]. Interestingly,
in the NHE1-induced CH model of mice, knocking out OPN was sufficient to significantly reduce
collagen deposition, upregulation of CD44, and phosphorylation of RSK, features that are characteristic
of cardiac fibrosis [39]. Taken together, these findings suggest that benefits from knocking out OPN
could be possible in specific settings of cardiac dysfunction, including diabetes, CH, and heart failure.
Recent genome-editing tools have emerged as powerful methods, which enable the generation of
genetically modified cells and organisms necessary to elucidate gene function and mechanisms
of human disease. Such tools include the use of RNA interference, specifically exogenously
derived small interfering RNA (siRNA), and clustered regularly interspersed short palindromic
repeats/CRISPR-associated protein 9 (CRISPR/Cas9) gene-editing technologies [61]. More specific
means of OPN inhibition have also received special attention recently, including the use of siRNA
technology. Mohamed et al. demonstrated that transfection of cardiomyocytes with siRNA-OPN
significantly improved the NHE1-induced hypertrophic response in cardiomyocytes [13]. More
specifically, inhibition of OPN using siRNA was able to significantly reduce cell surface area, total
protein content, atrial natriuretic peptide (ANP) mRNA expression as well as GATA4 phosphorylation,
compared to cardiomyocytes expressing active NHE1 alone [13]. The potential of silencing OPN
as a means to revert CH is rather promising. However, it remains to be determined whether the
use of siRNA against OPN would be beneficial in attenuating fibrosis in a post-MI model, without
compromising cardiac function and left ventricular dilatation, as was previously demonstrated.
β-adrenergic receptor (AR) blockers have demonstrated significant survival benefits and have
become standard therapy for adults battling ischemic heart disease. Current appreciation of β-receptor
signaling involves activating pathways by which these receptors crosstalk with other signaling
pathways; making the β1-AR the “cardiotoxic subtype” whereas the β2-AR appears to be the
“cardioprotective” one [60]. While the more well-known β1-AR mediates the positive inotropic and
chronotropic actions of the sympathetic nervous system, β2-AR has been shown to exert several
cardioprotective effects in the heart post-MI, such as inhibition of fibrosis as well as inflammation and
apoptosis [5]. As a Gs protein-coupled receptor (GPCR), β2-AR antifibrotic effects have been attributed
to the stimulation and generation of cyclic 3′,5′-adenosine monophosphate (cAMP), which activates
both protein kinase A (PKA) and Epac, an exchange protein directly activated by cAMP known to
inhibit cardiac fibroblast activation and fibrosis [60]. Pollard et al. sought to delineate the role of
OPN on β-AR-regulated cardiomyoblast fibrosis, using the H9c2 rat cardiac myoblast cell line [60].
Interestingly, the study demonstrated that CRISPR-mediated OPN deletion enriched the release of
cAMP, leading to the upregulation of Epac protein levels, and abrogating TGF-β-induced fibrosis,
in response to β2-AR activation in H9c2 cells [60]. This data further supports the notion that specific
OPN-blockade can significantly boost the therapeutic efficacy of cardioprotective pathways, such as
the β2-AR, against cardiac fibrosis.
The use of cell-permeable OPN function-blocking antibodies have revealed that not only is
OPN an important contributor to myocardial fibrosis, but it could possibly mitigate remodeling of
the heart following injury [15,56]. This was demonstrated in a recent study, in which the genetic
model of heart failure (cardiac-specific integrin-linked kinase (ILK) knockout) mice were injected
intraperitoneally with a neutralizing anti-mouse OPN polyclonal goat immunoglobulin G [56]. Upon
preforming echocardiography, Dai et al. revealed that the OPN-specific antibody could improve the
functional decline in cardiac-specific ILK knockout mice when compared to the control mice [56].
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However, blocking OPN appeared to only mitigate rather than fully rescue the functional decline
in the mice, suggesting that OPN treatment for a transient period of time alone may be insufficient
to reverse cardiac dysfunction and fibrosis. In a later study, Li et al. demonstrated that blocking
OPN at the time of surgeries with an aptamer (small structured single-stranded nucleic acid ligands,
which have emerged as alternatives to antibodies) and at two months post-surgeries, in the mouse
model of pressure overload, prevented cardiomyocyte hypertrophy and cardiac fibrosis, reduced
expression of ECM components (FN1, lumican, and collagen type III α1 chain) and re-expression of
the fetal genes, prevented cardiac dysfunction and blocked OPN downstream signaling (PI3K/Akt
phosphorylation), and reversed cardiac dysfunction, fibrosis, and hypertrophy [15]. Taken together,
these studies demonstrate that blocking and/or powering down cardiac OPN signaling in a time-specific
manner may be more effective at reversing CH and fibrosis, thus improving cardiac function.
6. OPN as A Biomarker
Although several studies have demonstrated the efficacy of OPN inhibition in a variety of
preclinical models of cardiovascular disease, clinical applications have not yet been demonstrated, since
the detailed and long-term effects of blocking OPN signaling on the heart remain poorly understood.
That being said, OPN is not only considered a pivotal protein controlling myocardial fibrosis, it
is becoming increasingly popular as a biomarker associated with the prognosis of cardiovascular
disease [7,28]. This has been demonstrated in a study by Dimitrow et al. in which a statistically
significant decrease in OPN levels was observed in 33 patients battling heart disease following
atorvastatin treatment for four weeks [28]. Correlations between OPN levels and diabetic vascular
complications and all-cause mortality in patients with type 1 diabetes was also demonstrated in the
FinnDiane study, in which serum OPN levels were significantly higher at baseline in patients who
experienced a cardiovascular disease event compared to those who did not [62]. Collectively, these
data demonstrate the potential of using OPN levels to detect the existence and severity of coronary
artery disease and its complications.
OPN expression has also been correlated with the onset of heart failure in both animal models [12]
and clinical settings [51,63]. Trueblood et al. demonstrated in a rat model that OPN levels were
increased following the transition from left ventricular hypertrophy to cardiac decompensation [59].
The upregulation of OPN mRNA was suggested to originate from infiltrating macrophages and
fibroblasts in the interstitium, suggesting that the role of OPN during heart failure could be attributed
to its pro-inflammatory effects [14]. Clinically, during the early stages of acute ST-elevation MI
and in patients who had undergone reperfusion within 12 h of the onset of anterior-wall acute MI,
plasma levels of OPN have been shown to be elevated [64,65]. Additionally, in the subset of patients
who underwent successful reperfusion following anterior-wall acute MI, reduction in OPN plasma
levels was significantly correlated with the left ventricular end-systolic and diastolic volume index
as well as ejection fraction [65]. Moreover, in patients undergoing cardiac resynchronization therapy
(CRT), an effective treatment for heart failure in patients with ventricular dyssynchrony, plasma OPN
levels were significantly lower in responders to CRT compared to non-responders [66]. Furthermore,
in a recent study where the role of OPN in hypertension-induced heart failure was investigated, plasma
levels of OPN appeared to be significantly higher in the hearts of patients with heart failure compared
to control hearts [51]. Collectively, these observations suggest that elevated plasma levels of OPN
could serve as a biomarker of the occurrence of an MI incident, as well as an indicator of the severity of
heart failure and an indicator of the response to heart failure therapies.
7. Conclusions
Cardiac fibrosis is characterized by the net accumulation of extracellular matrix in the myocardium
and is an integral component of most cardiac pathologic conditions. In our review article, we highlighted
the relevance of OPN in contributing to the intercellular signals required to integrate myofibroblast
proliferation, migration, and ECM deposition. In addition, we discussed the significance of OPN
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activity in both myocytes and fibroblasts experiencing stress, and that elevated plasma levels of OPN
could serve as a biomarker of the occurrence of an MI incident, as well as an indicator of the severity of
heart failure and the response to heart failure therapies. Furthermore, inhibition of selected pathways
or ligands involved in the OPN pathway may be of therapeutic benefit for the prevention of further
cardiac damage and dysfunction. These findings suggest the pivotal role of OPN in cardiac fibrosis
and remodeling and that a better understanding of the role of OPN in the pathogenesis of cardiac
fibrosis could hold the key to the identification of promising targets for the treatment of patients with
heart failure. Whether the use of more specific inhibition or deletion of OPN in the heart post-MI could
be more beneficial for cardiac fibrosis remains unclear.
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